$11.00
6.08% yesterday
Nasdaq, May 20, 09:46 pm CET
ISIN
US14070B1017
Symbol
CAPR
Sector
Industry

Capricor Therapeutics, Inc. Stock price

$11.01
-0.91 7.63% 1M
-7.91 41.81% 6M
-2.79 20.22% YTD
+4.71 74.76% 1Y
+7.53 216.38% 3Y
+6.02 120.64% 5Y
-46.99 81.02% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.64 6.17%
ISIN
US14070B1017
Symbol
CAPR
Sector
Industry

Key metrics

Market capitalization $503.24m
Enterprise Value $363.09m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 20.92
P/S ratio (TTM) P/S ratio 28.99
P/B ratio (TTM) P/B ratio 3.94
Revenue growth (TTM) Revenue growth -35.92%
Revenue (TTM) Revenue $17.36m
EBIT (operating result TTM) EBIT $-57.28m
Free Cash Flow (TTM) Free Cash Flow $-47.18m
Cash position $144.78m
EPS (TTM) EPS $-1.42
P/E forward 34.41
P/S forward 4.25
EV/Sales forward 3.07
Short interest 25.76%
Show more

Is Capricor Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Capricor Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Capricor Therapeutics, Inc. forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Capricor Therapeutics, Inc. forecast:

Buy
100%

Financial data from Capricor Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
17 17
36% 36%
100%
- Direct Costs 1.50 1.50
29% 29%
9%
16 16
39% 39%
91%
- Selling and Administrative Expenses 15 15
29% 29%
85%
- Research and Development Expense 57 57
45% 45%
328%
-56 -56
125% 125%
-321%
- Depreciation and Amortization 1.50 1.50
29% 29%
9%
EBIT (Operating Income) EBIT -57 -57
121% 121%
-330%
Net Profit -55 -55
126% 126%
-317%

In millions USD.

Don't miss a Thing! We will send you all news about Capricor Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Capricor Therapeutics, Inc. Stock News

Positive
Seeking Alpha
about 18 hours ago
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough.
Neutral
Seeking Alpha
7 days ago
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marban - Chief Executive Officer Conference Call Participants Ed Tenthoff - Piper Sandler Leland Gershell - Oppenheimer Kristen Kluska - Cantor Fitzgerald Catherine Novack - Jones Research Aydin Huseynov - Ladenburg Maanasa Sangee...
Neutral
GlobeNewsWire
15 days ago
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. Management will then host a webcast and conference call at 4:30 p.m.
More Capricor Therapeutics, Inc. News

Company Profile

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.

Head office United States
CEO Linda Marbán
Employees 160
Founded 1996
Website www.capricor.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today